
Mounir Wz Basalus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5749902/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients. Journal of the American College of Cardiology, 2012, 59, 1350-1361.	2.8	229
2	Clinical Outcome Following Stringent DiscontinuationÂofÂDual Antiplatelet Therapy AfterÂ12ÂMonths in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute andÂEverolimus-Eluting Xience V Stents. Journal of the American College of Cardiology, 2013, 61, 2406-2416.	2.8	68
3	Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. EuroIntervention, 2009, 5, 157-165.	3.2	64
4	Usefulness and safety of the GuideLiner catheter to enhance intubation and support of guide catheters: insights from the Twente GuideLiner registry. EuroIntervention, 2012, 8, 336-344.	3.2	57
5	Micro-computed tomographic assessment following extremely oversized partial postdilatation of drug-eluting stents. EuroIntervention, 2010, 6, 141-148.	3.2	33
6	Scanning electron microscopic assessment of coating irregularities and their precursors in unexpanded durable polymerâ€based drugâ€eluting stents. Catheterization and Cardiovascular Interventions, 2012, 79, 644-653.	1.7	26
7	Scanning electron microscopic assessment of the biodegradable coating on expanded biolimus-eluting stents. EuroIntervention, 2009, 5, 505-510.	3.2	24
8	DUrable polymer-based sTent CHallenge of Promus ElemEnt versus ReSolute integrity (DUTCH PEERS): Rationale and study design of a randomized multicenter trial in a Dutch all-comers population. American Heart Journal, 2012, 163, 557-562.	2.7	22
9	Comparison of Frequency of Periprocedural Myocardial Infarction in Patients With and Without Diabetes Mellitus to Those With Previously Unknown but Elevated Glycated Hemoglobin Levels (from) Tj ETQq1	1 07 8431	4 æð /Over
10	Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and XIENCE V drug-eluting stents. EuroIntervention, 2012, 8, 664-671.	3.2	19
11	Polymer coatings on drug-eluting stents: Samson's hair and Achilles' heel?. EuroIntervention, 2013, 9, 302-305.	3.2	19
12	Benchside testing of drug-eluting stent surface and geometry. Interventional Cardiology, 2010, 2, 159-175.	0.0	15
13	Clinical outcome of patients with implantation of secondâ€generation drugâ€eluting stents in the right coronary ostium: Insights from 2â€year followâ€up of the TWENTE trial. Catheterization and Cardiovascular Interventions, 2015, 85, 524-531.	1.7	14
14	Effect of Oversized Partial Postdilatation on Coatings of Contemporary Durable Polymer-Based Drug-Eluting Stents: A Scanning Electron Microscopy Study. Journal of Interventional Cardiology, 2011, 24, 149-161.	1.2	12
15	Incidence of periprocedural myocardial infarction following stent implantation: Comparison between first―and secondâ€generation drugâ€eluting stents. Catheterization and Cardiovascular Interventions, 2012, 80, 524-530.	1.7	10
16	Women treated with secondâ€generation zotarolimusâ€eluting resolute stents and everolimusâ€eluting xience V stents: insights from the genderâ€stratified, randomized, controlled TWENTE trial. Catheterization and Cardiovascular Interventions, 2013, 82, 396-405.	1.7	8
17	Complex patients treated with zotarolimusâ€eluting resolute and everolimusâ€eluting xience V stents in the randomized TWENTE trial: Comparison of 2â€year clinical outcome. Catheterization and Cardiovascular Interventions, 2015, 85, 74-81.	1.7	7
18	Recent insights from scanning electron microscopic assessment of durable polymer-coated drug-eluting stents. Interventional Cardiology, 2012, 4, 661-674.	0.0	4

#	Article	IF	CITATIONS
19	On the loss of the phosphorylcholineâ€based DES coating on the abluminal surface of endeavor stents. Catheterization and Cardiovascular Interventions, 2010, 76, 158-159.	1.7	3
20	Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial. EuroIntervention, 2014, 10, 664-671.	3.2	2